Loading...
Loading...
- Novo Nordisk A/S (NYSE: NVO) posted better than expected fourth-quarter earnings but said that sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment, due to social-distancing regulations. The company also said that for continuing trials, recruitment of new patients is still below pre-coronavirus levels.
- The fourth quarter had strong sales growth within diabetes and obesity care, partially offset by lower insulin sales, fewer new patients due to COVID-19, higher unemployment in the U.S., and COVID-related destocking.
- The quarter's net profit rose to DKK 9.32 billion, while sales slipped at a rate of 0.9% to DKK 32.1 billion.
- The company expects full-year 2021 annual sales growth of 5% to 9% and operating profit growth of 4% to 8% in local currencies, reflecting sales growth of diabetes-care products Ozempic and Rybelsus as well as growth within obesity care.
- The board proposed a final dividend of DKK5.85 a share for 2020 and intends to initiate a new 12-month share repurchase program of up to DKK 17 billion.
- NVO shares increased 3.8% at $73.65 in pre-market trading on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in